Such heavy intoxication is highly likely to contribute to FASD. Historical references
Admonitions against prenatal alcohol use from ancient Greek, Roman, Talmudic, and possibly Biblical sources indicate a historical awareness of links between alcohol use and fetal development, although sources rarely if ever distinguish maternal alcohol consumption from paternal. For example, Plato writes in his fourth-century B.C. Laws (6.775): "Drinking to excess is a practice that is nowhere seemly [...] nor yet safe. [...] It behooves both bride and bridegroom to be sober [...] in order to ensure, as far as possible, in every case that the child that is begotten may be sprung from the loins of sober parents." Likewise, the sixth-century A.D. Talmud (Kethuboth 60b) cautions, "One who drinks  intoxicating liquor will have ungainly children." In such ancient sources, the warnings against alcohol consumption for fetal development are more frequently concerned with conception than pregnancy. In 1725, British physicians petitioned the House of Commons on the effects of strong drink when consumed by pregnant women saying that such drinking is "too often the cause of weak, feeble, and distempered children, who must be, instead of an advantage and strength, a charge to their country." There are many other such historical references. In Gaelic Scotland, the mother and nurse were not allowed to consume ale during pregnancy and breastfeeding.
Watchful Waiting
Some patients do not require immediate treatment after diagnosis; these patients include those that do not show overt symptoms or whose cancer has not been observed to be progressing. Regular check-ups with physicians are required to actively monitor the patients condition; once there is evidence of disease progression or patient distress from symptoms, treatment will be implemented. Chemotherapy
B-PLL has a very aggressive clinical course and refractoriness to chemotherapy; it is believed this resistance is the result of mutations to the TP53 gene. Its resistant nature has led to the use of combinations of chemotherapy drugs. Drug regimens recommended and employed by physicians are unique to each patient and are based on previous chemotherapy experience along with potential side effects. In addition to the utilization of combinations of chemotherapeutic drugs, it is most often paired with immunotherapy treatments. Targeted Therapy
Monoclonal Antibodies
A type of targeted therapy that recognizes specific proteins in leukemia cells preventing collateral damage to normal, healthy cells. The following are compounds currently showing promising results in clinical trials and studies:

Rituximab is a widely used monoclonal antibody in treating B-cell malignancies, it is directed against the surface protein CD20. Case studies have documented successful treatment of B-PLL solely with rituximab; additional studies have reported positive activity when rituximab is paired with the chemotherapeutic drugs fludarabine or bendamustine together with the anthracyclines mitoxantrone or epirubicin
Alemtuzumab is a humanized antibody that targets the CD52 antigen which is highly expressed in malignant B-lymphocytes. In vitro tests have demonstrated that it induces cell death.